Search

Brucellosis is a highly contagious zoonosis caused by bacteria of the genus Brucella and affecting domestic and wild mammals. In this paper, the bacteriological and serological evidence of brucellosis in Sub-Saharan Africa (SSA) and its epidemiological characteristics are discussed. The tools available for the diagnosis and treatment of human brucellosis and for the diagnosis and control of animal brucellosis and their applicability in the context of SSA are presented and gaps identified. These gaps concern mostly the need for simpler and more affordable antimicrobial treatments against human brucellosis, the development of a B. melitensis vaccine that could circumvent the drawbacks of the currently available Rev 1 vaccine, and the investigation of serological diagnostic tests for camel brucellosis and wildlife. Strategies for the implementation of animal vaccination are also discussed. [ABSTRACT FROM AUTHOR]

Abstract: Soil-transmitted helminthiasis (STH) occur throughout the developing world and remain a major public health problem in the poorest communities with enormous consequences on health and development of school-aged and preschool children. The extent of the problem has long been neglected because these diseases rarely kill at a young age, due to their insidious and chronic nature. Today there exists a momentum and an unprecedented opportunity for a cost-effective control of these neglected tropical diseases. The control of these diseases has become a priority on the agenda of many governments, donors and international agencies, which provides important funding opportunities for STH control through integration and co-implementation of control interventions. In the era of preventive chemotherapy, the intensification of mass administration of anthelminthic drugs will result in epidemiological changes of STH transmission levels, with a rapid increase of light infections as far as control programmes are successful. As consequence, the current diagnostic tools may not be always appropriate and may therefore require adaptation or development of alternative assays adapted to the stage of control. This paper reviews aspects relevant to diagnosis and appropriate tools for accurate surveillance and monitoring of STH control programmes and drug efficacy. Prospects, opportunities and challenges for the control are discussed. [Copyright &y& Elsevier]